The report: www.medpac.gov/wp-content/u...
13.03.2025 18:34 β π 0 π 0 π¬ 0 π 0
This is because the value of supplemental benefits (the difference between an enhanced plan's cost sharing and what standard cost sharing would have been) now count towards the "true out of pocket cost"
Presumably another reason why bids came in so high.
13.03.2025 18:34 β π 0 π 0 π¬ 1 π 0
According to MedPAC, details of the Part D redesign mean that some enrollees will hit their $2,000 OOP maximum much faster than I realized.
In one example, they show how one could hit the max with just $470 in spending.
13.03.2025 18:34 β π 1 π 1 π¬ 1 π 0
I usually feel safe assuming a lawsuit! (But I donβt knowβ¦an insurer or PLF type group finds a test case).
17.12.2024 22:22 β π 2 π 0 π¬ 0 π 0
Do you have a guess for whether this is likely to survive a legal challenge, independent of what the next admin does? (Assuming someone sues).
17.12.2024 20:12 β π 1 π 0 π¬ 1 π 0
Ex NY Times, now author of Substack Paul Krugman. Nobel laureate and, according to Donald Trump, "Deranged BUM"
Health economist writing about HEOR/market access, drug development, biopharma
Http://refiningvalue.substack.com
Economist. Professor at University of Chicago, Harris Public Policy. I study the economics of healthcare β doctors, nurses, insurance, plus some labor and urban economics. www.gottlieb.ca
Health Economist. Associate Professor & Vice Chair for Research and Practice. Director, Center for Mental Health and Addiction Policy. Department of Health Policy and Management. Johns Hopkins University.
Economist. Associate Prof of Health Policy at Stanford. Mom of 2. Immigrant.
Health policy and economics. Some Prince, some Minnesota. Opinions my own.
Senior Scholar, Expanding Coverage and Access and Tracking Health System Performance at the Commonwealth Fund commonwealthfund.org.
economist | from NJ | he/him
Doctor @BrighamWomens | Associate Prof of Health Policy & Management @HarvardHPM @HarvardHSPH | @harvardmed | Faculty Director of BWH MLP Program
The American Society of Health Economists (ASHEcon) is a professional organization dedicated to promoting excellence in health economics research in the US.
Asst Prof @CarnegieMellon β’ Health and Behavioral economist β’ Enjoy limericks, fantasy, and mezcal β’ also go by Vini
https://www.manasvinisingh.com/
(opinions mine)
Co-Chair, Arnold Ventures
Stergachis Family Endowed Professor & Director, The CHOICE Institute (http://uwchoice.org), UW, Seattle, @amstatNews Fellow, @nberpubs RA. (he/him) π» β¬οΈ
A nonpartisan research and policy institute that advances federal and state policies to help build a nation where everyone has the resources they need to thrive and share in the nationβs prosperity.
The latest news & views about the pharmaceutical industry - and other stray thoughts - from Ed Silverman.. ex-WSJ .. statnews.com/pharmalot/
Medicare expert. Deputy Director, Program on Medicare Policy @KFF. Part D, prescription drug policy, Medicare spending & financing, cyclist, NYT spelling bee fanatic.
Medical oncologist and health services researcher. Focusing on health care costs, physician-industry COI, and oncology reimbursement reform. Opinions mine.
Project Director of the KFF Project on Hospital Costs
https://www.kff.org/person/zachary-levinson/
Assistant Professor of Health Policy and Politics at @hsph.harvard.edu
I study how administrative burdens impede health insurance coverage, strategies to reduce these barriers, and the politics of health reform
she/her/Michigander
University of Michigan Law Professor